ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » New Jersey » Hematology Oncology

Top Hematology Oncology Prescribers in New Jersey

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
YOLETTE STERLING M.D.

Hematology Oncology

4,837

$252K

321
217 are 65+

0%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 24%

$52
Average prescription price

Avg: $494

JUHEE GUPTA MD

Hematology Oncology

4,653

$399K

289
219 are 65+

10%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

29%
prescriptions for brand name drugs

Avg: 24%

$86
Average prescription price

Avg: $494

MICHAEL WAX MD

Hematology Oncology

4,260

$1.63M

380
354 are 65+

14%
patients receiving schedule two controlled substances

Avg: 15%

3%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

27%
prescriptions for brand name drugs

Avg: 24%

$383
Average prescription price

Avg: $494

EDWARD GOLD M.D.

Hematology Oncology

3,174

$276K

301
282 are 65+

4%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

33%
prescriptions for brand name drugs

Avg: 24%

$87
Average prescription price

Avg: $494

HARVEY COOPER MD

Hematology Oncology

3,059

$236K

162
156 are 65+

0%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

31%
prescriptions for brand name drugs

Avg: 24%

$77
Average prescription price

Avg: $494

CHITRA KUMAR MD

Hematology Oncology

2,945

$265K

132
114 are 65+

12%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

39%
prescriptions for brand name drugs

Avg: 24%

$90
Average prescription price

Avg: $494

MARIE SANGOSSE MD

Hematology Oncology

2,659

$180K

137
107 are 65+

22%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

34%
prescriptions for brand name drugs

Avg: 24%

$68
Average prescription price

Avg: $494

DEVARAJAN IYENGAR M.D.

Hematology Oncology

2,385

$2.15M

147
124 are 65+

21%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

29%
prescriptions for brand name drugs

Avg: 24%

$902
Average prescription price

Avg: $494

NIRMALA SARAF M.D.

Hematology Oncology

2,275

$414K

128
98 are 65+

25%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

35%
prescriptions for brand name drugs

Avg: 24%

$182
Average prescription price

Avg: $494

SHEUE H. LEE MD

Hematology Oncology

2,234

$265K

99
90 are 65+

0%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

45%
prescriptions for brand name drugs

Avg: 24%

$119
Average prescription price

Avg: $494

KENNETH NAHUM D.O.

Hematology Oncology

2,203

$1.25M

376
324 are 65+

15%
patients receiving schedule two controlled substances

Avg: 15%

13%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 24%

$568
Average prescription price

Avg: $494

MICHAEL NISSENBLATT MD

Hematology Oncology

2,070

$978K

263
230 are 65+

13%
patients receiving schedule two controlled substances

Avg: 15%

6%
patients receiving schedule three controlled substances

Avg: 1%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

30%
prescriptions for brand name drugs

Avg: 24%

$473
Average prescription price

Avg: $494

NIRMALA KANIA M.D.

Hematology Oncology

1,991

$529K

255
193 are 65+

6%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

33%
prescriptions for brand name drugs

Avg: 24%

$266
Average prescription price

Avg: $494

MARY CHOLANKERIL MD

Hematology Oncology

1,976

$336K

104
74 are 65+

0%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 24%

$170
Average prescription price

Avg: $494

JOSEPH WILDMAN MD

Hematology Oncology

1,954

$258K

110
105 are 65+

0%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

31%
prescriptions for brand name drugs

Avg: 24%

$132
Average prescription price

Avg: $494

TASNEEM RASHID MD

Hematology Oncology

1,831

$234K

139
107 are 65+

0%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

34%
prescriptions for brand name drugs

Avg: 24%

$128
Average prescription price

Avg: $494

STANLEY WAINTRAUB MD

Hematology Oncology

1,700

$591K

310
274 are 65+

7%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 24%

$347
Average prescription price

Avg: $494

DAVID SIEGEL MD

Hematology Oncology

1,666

$5.36M

208
166 are 65+

19%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

50%
prescriptions for brand name drugs

Avg: 24%

$3217
Average prescription price

Avg: $494

SCOTT ROWLEY MD

Hematology Oncology

1,628

$258K

149
89 are 65+

20%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 24%

$159
Average prescription price

Avg: $494

THOMAS RAKOWSKI M.D.

Hematology Oncology

1,614

$773K

301
279 are 65+

9%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 24%

$479
Average prescription price

Avg: $494

INDU SHARMA M.D.

Hematology Oncology

1,584

$689K

206
178 are 65+

13%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

30%
prescriptions for brand name drugs

Avg: 24%

$435
Average prescription price

Avg: $494

PETER YI M.D.

Hematology Oncology

1,536

$874K

191
177 are 65+

13%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 24%

$569
Average prescription price

Avg: $494

STEPHEN ABO D.O.

Hematology Oncology

1,505

$264K

136
110 are 65+

11%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 24%

$175
Average prescription price

Avg: $494

ROBERT ALTER MD

Hematology Oncology

1,483

$970K

221
191 are 65+

24%
patients receiving schedule two controlled substances

Avg: 15%

6%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

27%
prescriptions for brand name drugs

Avg: 24%

$654
Average prescription price

Avg: $494

ELI KIRSHNER MD

Hematology Oncology

1,441

$194K

145
130 are 65+

11%
patients receiving schedule two controlled substances

Avg: 15%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 24%

$135
Average prescription price

Avg: $494

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank